Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -70.67% is 28% below its 5-year average of -55.25%, near the low end of its 5-year range (-88.11%–-25.85%).
38.42% below its 12-month average of -51.05%.
Reported quarterly return on assets; no daily interpolation. Q1 FY2027 (2026-06-30): -17.97%.
RETURN ON ASSETS (ROA)
-70.67%
RETURN ON ASSETS (ROA) AVG TTM
-51.05%
RETURN ON ASSETS (ROA) AVG 3Y
-54.02%
RETURN ON ASSETS (ROA) AVG 5Y
-55.25%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-38.42%
CURRENT VS 3Y AVG
-30.83%
CURRENT VS 5Y AVG
-27.91%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-119.20%
vs the sector median at left
Helus Pharma Inc.
Market Cap
$669.43M
Return on Assets (ROA)
-70.67%
TTM Avg
-51.05%
3Y Avg
-54.02%
5Y Avg
-55.25%
Market Cap
$669.66M
Return on Assets (ROA)
-36.37%
TTM Avg
-26.71%
3Y Avg
-31.04%
5Y Avg
-27.33%
Market Cap
$670.94M
Return on Assets (ROA)
-82.36%
TTM Avg
-56.97%
3Y Avg
-52.21%
5Y Avg
-45.34%
Market Cap
$662.92M
Return on Assets (ROA)
2.22%
TTM Avg
15.13%
3Y Avg
10.21%
5Y Avg
1.65%
Market Cap
$668.36M
Return on Assets (ROA)
-41.48%
TTM Avg
-39.59%
3Y Avg
-35.47%
5Y Avg
-52.36%
Market Cap
$656.34M
Return on Assets (ROA)
-20.36%
TTM Avg
-36.81%
3Y Avg
-36.81%
5Y Avg
-36.81%
Market Cap
$683.73M
Return on Assets (ROA)
-49.24%
TTM Avg
-70.53%
3Y Avg
-58.08%
5Y Avg
-52.49%
Market Cap
$687.91M
Return on Assets (ROA)
-98.15%
TTM Avg
-106.83%
3Y Avg
-87.42%
5Y Avg
-76.51%
Market Cap
$690.20M
Return on Assets (ROA)
-36.26%
TTM Avg
-29.77%
3Y Avg
-47.75%
5Y Avg
-50.63%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Helus Pharma Inc. (HELP) | $669.43M | -70.67% | -51.05% | -54.02% | -55.25% |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $669.66M | -36.37% | -26.71% | -31.04% | -27.33% |
| Annexon, Inc. (ANNX)vs › | $670.94M | -82.36% | -56.97% | -52.21% | -45.34% |
| MiMedx Group, Inc. (MDXG)vs › | $662.92M | 2.22% | 15.13% | 10.21% | 1.65% |
| ArriVent BioPharma, Inc. (AVBP)vs › | $668.36M | -41.48% | -39.59% | -35.47% | -52.36% |
| Starling Oncology, Inc. (STLN)vs › | $656.34M | -20.36% | -36.81% | -36.81% | -36.81% |
| Solid Biosciences Inc. (SLDB)vs › | $683.73M | -49.24% | -70.53% | -58.08% | -52.49% |
| Verastem, Inc. (VSTM)vs › | $687.91M | -98.15% | -106.83% | -87.42% | -76.51% |
| Wave Life Sciences Ltd. (WVE)vs › | $690.20M | -36.26% | -29.77% | -47.75% | -50.63% |
| Anteris Technologies Global Corp. (AVR)vs › | $693.75M | -38.01% | -251.96% | -211.47% | -174.45% |
ROA
-70.7%
ROE
-75.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2026-03-31 | -58.36% |
| 2025-03-31 | -43.75% |
| 2024-03-31 | -25.85% |
| 2023-03-31 | -88.11% |
| 2022-03-31 | -80.45% |
| 2021-03-31 | -34.98% |
| 2020-03-31 | -113.62% |
| 2019-07-31 | -24.73% |
| 2018-07-31 | -48.40% |
| 2017-07-31 | -28.66% |
